Stop RFK’s BS Act
- Bill Number
- H.R. 5609
- Origin Chamber
- House
- Congress
- 119th Congress, Session 1
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2025-09-26: Referred to the House Committee on Energy and Commerce.
- Last Updated
- 2025-12-16T18:54:02Z
AI-Generated Summary
Purpose
The legislation aims to restore funding for National Institutes of Health (NIH) grants and awards that were terminated or suspended between January 20, 2025, and the date the bill becomes law, unless specific issues like financial mismanagement are found. It seeks to ensure continuity in NIH-funded research by reinstating these funds and extending project timelines.
Key Provisions
- Reinstatement Requirement: Starting on the date of enactment, any NIH grants or awards ended or paused during the specified period must be reinstated and treated as fully committed (obligated) funds, unless the NIH Director determines there was financial mismanagement, research fraud, or wrongdoing (malfeasance) involved.
- Payment Processing: Recipients can submit payment requests to NIH officials, which must be paid out as quickly as possible and no later than 30 days after submission.
- Timeline Extension: For reinstated or paid-out grants/awards, the project's budget period (the set time frame for spending funds, as defined in NIH policy) is automatically extended by one year from the enactment date.
- Definitions:
- Budget period: The designated timeframe for using grant funds, per NIH's Grants Policy Statement (April 2024).
- Covered grant or award: Any funding provided by NIH officials under laws they administer.
- NIH official: Includes the NIH Director and others responsible for awarding federal research funds.
Significant Changes to Existing Law
This bill introduces a mandatory reversal of NIH funding decisions made in early 2025, overriding prior terminations or suspensions without requiring new justification beyond the specified exceptions. It also mandates faster payment processing (within 30 days) and automatic one-year extensions, which are not standard under current NIH grant policies that typically allow terminations for administrative or policy reasons without such automatic reinstatement.
Potential Impacts
- Government Agencies: The NIH would face administrative burdens to review and reinstate grants quickly, potentially straining resources and requiring policy adjustments to comply with the 30-day payment rule.
- Citizens and Researchers: Scientists, universities, and medical researchers who lost funding could resume projects, supporting ongoing health and science work that benefits public health. Delays in reinstatement might temporarily disrupt research progress.
- International Relations: Minimal direct impact, though it could affect collaborative international research projects funded by NIH if those grants were suspended.
Main Stakeholders Affected
- NIH and Federal Officials: Directly responsible for implementing reinstatements, payments, and extensions.
- Grant Recipients: Primarily academic institutions, researchers, and organizations that received NIH funding, who stand to regain financial support.
- Taxpayers: Indirectly affected through continued allocation of federal research dollars, potentially influencing the pace of medical advancements.
Notable Legal, Constitutional, or Political Implications
- Legal: The bill enforces accountability on NIH decisions by limiting terminations to proven misconduct, potentially challenging executive authority over agency funding if prior suspensions were policy-based. It could lead to legal disputes if the NIH Director's findings on mismanagement or fraud are contested in court.
- Constitutional: Raises questions about separation of powers, as Congress is directing specific agency actions, which might be seen as interfering with executive branch discretion over grant administration.
- Political: The bill's title references "RFK" (likely alluding to a public figure's influence on science policy), suggesting it responds to perceived politically motivated changes in NIH funding. This could polarize debates on science funding independence versus congressional oversight, without altering core constitutional protections for free speech or due process in research.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Rep. Stevens, Haley M. [D-MI-11]
Cosponsors (1)
Recent Actions
- 2025-09-26: Referred to the House Committee on Energy and Commerce.
- 2025-09-26: Introduced in House
- 2025-09-26: Introduced in House
Bill Versions
- Stop RFK’s Bad Science Act — issued 2025-09-26 — PDF (3 pages)